PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and c ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and c ...

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 250 points on Monday.The Dow traded up 1.66% to 49,183.51 while the NASDAQ gained 0.80% to 23,420.85. The S&P 500 also rose, gaining, 0.81% to 6,913.76.Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 5% Dividend YieldsLeading and Lagging SectorsEnergy shares gained by 2.9% on Monday.In trading on Monday, utilities stocks dipped by 2.2%.Top HeadlineThe ISM manufactur ...

Core Viewpoint - Palisade Bio, Inc. is advancing PALI-2108, a novel PDE4 inhibitor targeting ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), addressing significant unmet medical needs in these conditions [1][3] Intellectual Property - The Japan Patent Office has granted a key patent for PALI-2108, providing composition-of-matter protection until 2041, with potential extensions based on regulatory review timelines [2] - This patent strengthens Palisade Bio's global intellectual property portfolio, supporting the development of PALI-2108 and its broader platform of locally activated PDE4 inhibitor prodrugs [2][3] Clinical Development - PALI-2108 has completed Phase 1a studies and is currently in a Phase 1b cohort study for both UC and FSCD, with Phase 2 IND submissions planned for the first half of 2026 [1][3][6] - In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, demonstrating favorable tolerability and pharmacokinetics [6] Mechanism and Design - PALI-2108 is designed for local delivery of PDE4 inhibition specifically to the terminal ileum and colon, minimizing systemic exposure and enhancing therapeutic index [4] - The prodrug is activated by gut microbiota, ensuring targeted release at the site of inflammation and fibrosis, which aims to improve anti-inflammatory and anti-fibrotic effects while reducing common side effects associated with systemic PDE4 inhibitors [4][6] Future Plans - The company is preparing to initiate a Phase 2 clinical study in UC to evaluate clinical remission and pharmacodynamic biomarkers over 12 weeks, with an extension phase for maintenance of remission [7] - Additionally, studies in FSCD are planned to further characterize the safety and therapeutic benefits of PALI-2108 across inflammatory bowel disease indications [7]

U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Monday.Shares of DigitalBridge Group Inc (NYSE:DBRG) rose sharply during Monday's session after the company announced it will be acquired by SoftBank Group for a total enterprise value of approximately $4.0 billion.DigitalBridge Group shares jumped 9.9% to $15.30 on Monday.Here are some other big stocks recording gains in today’s session.Eightco Holdings Inc (NASDAQ:ORBS) shares jumped 29.1% to $2.15 after the company announce ...

Shares of Bolt Projects Holdings Inc (NASDAQ:BSLK) rose sharply in pre-market trading after the company announced preliminary fiscal 2025 results and updated its fiscal 2026 guidance.Bolt Projects raised its FY2026 sales guidance from $9.000 million to $11.000 million. The company said it sees fourth-quarter sales of $2.700 million.Bolt Projects Holdings shares jumped 28.2% to $1.73 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersRepublic Power Group Limited ...

We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Palisade Bio Inc. (NASDAQ:PALI) is one of the best performers on Wednesday. Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as investors loaded portfolios ahead of the results of its clinical trial for its treatment of fibrostenotic Crohn’s disease (FSCD). The company is targeting to present the topline results of its Phase 1b study of PALI-2108 in the first qu ...

Core Insights - Palisade Bio (PALI) is a clinical-stage biopharmaceutical company focused on developing PALI-2108, a prodrug candidate aimed at treating ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), both of which have significant unmet medical needs [1] Company Overview - PALI-2108 is being studied for two indications related to inflammatory bowel disease (IBD), specifically targeting ulcerative colitis and fibrostenotic Crohn's disease [1]

Core Insights - Palisade Bio (PALI) is a clinical-stage biopharmaceutical company focused on developing PALI-2108, a prodrug candidate aimed at treating ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), both of which have significant unmet medical needs [1] Company Overview - PALI-2108 is being studied for two indications related to inflammatory bowel disease (IBD), specifically targeting ulcerative colitis and fibrostenotic Crohn's disease [1] Market Opportunity - The conditions targeted by PALI-2108 represent significant unmet medical needs, indicating a potential market opportunity for the company [1]

Palisade Bio, Inc. (PALI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a c ...